Compare Booz Allen Hamilton Holding Corporation (BAH) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Booz Allen Hamilton Holding Corporation vs Merck & Co., Inc. — how do they compare? Booz Allen Hamilton Holding Corporation trades at $78.27 (market cap $9.45B), while Merck & Co., Inc. trades at $133.68 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 34× Booz Allen Hamilton Holding Corporation's market cap, and Booz Allen Hamilton Holding Corporation pays the higher dividend (3%). Which is the better fit depends on your goals.
| BAH | MRK | |
|---|---|---|
Market Cap | $9.45B | $321.77B |
Sector | Industrials | Health |
52-Week High | $111.63 | $131.84 |
52-Week Low | $59.71 | $77.60 |
Enterprise Value | $13.07B | $368.53B |
Dividend Yield | 3% | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Booz Allen Hamilton (BAH) trades at $77.93, up 0.04% on the day, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a 7.01% net margin and 68.11% ROE, while valuation ratios like P/E of 12.33 and P/S of 0.86 appear attractive. Recent Q2 2026 earnings beat estimates at $1.81 per share, and the company maintains consistent dividend payments, reflecting financial stability.
Outlook remains positive with analyst consensus price target of $84.67, though risks include high debt levels and civil revenue weakness. Growth in national security and AI investments offers upside, but investors should monitor leverage and sector-specific headwinds for balanced exposure.
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
